Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804318 · ClinicalTrials.gov registry record · NA
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
A NA study of Prostate Cancer, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 7
- Study locations
NCT05804318: Recruiting NA study of Prostate Cancer, sponsored by Varian, a Siemens Healthineers Company.
NCT05804318 is a NA study of Prostate Cancer that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 132 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05804318, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 7
- Study locations
Study Summary
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Primary Outcome
Minimum clinically important change (MCIC) status in patient-reported urinary QOL, as determined by the worst change reported by each subject in their EPIC-26 urinary domain scores.
Conditions Studied
Interventions
- DEVICE Daily adaptive SBRT with urethral sparing
Study Locations (7)
California
- Duarte Cancer Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
Massachusetts
- Brigham and Women's Hospital - Boston
Missouri
- Washington University in St. Louis - St Louis
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Saarland
- Universitätsklinikum des Saarlandes (Saarland Univerisity Hospital) - Homburg
Navarre
- Hospital Universitario de Navarra - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2031-07 |
| Phase | NA |
What NCT05804318 shows while recruiting
NCT05804318 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Daily adaptive SBRT with urethral sparing is the first listed.
NCT05804318 lists 7 locations in 6 states (California, Massachusetts, Missouri).
Frequently Asked Questions
What is clinical trial NCT05804318 about?
NCT05804318 is a clinical study titled "Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer". This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the p...
What is the current status of trial NCT05804318?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2023-04-13. Estimated completion is 2031-07.
What conditions does trial NCT05804318 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05804318?
The interventions under investigation include: Daily adaptive SBRT with urethral sparing (DEVICE).
Who is sponsoring clinical trial NCT05804318?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804318 being conducted?
This trial has 7 study locations across California, Massachusetts, Missouri, Pennsylvania, Saarland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05804318's enrollment target sits among peer trials
132 288th of 735 higher than 447 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI